Compare KLAR & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KLAR | PEN |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 12.2B |
| IPO Year | 2025 | 2015 |
| Metric | KLAR | PEN |
|---|---|---|
| Price | $25.55 | $359.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 18 |
| Target Price | $46.64 | ★ $350.94 |
| AVG Volume (30 Days) | ★ 2.8M | 1.5M |
| Earning Date | 02-25-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 367.34 |
| EPS | N/A | ★ 4.14 |
| Revenue | ★ $3,209,000,000.00 | $1,333,798,000.00 |
| Revenue This Year | $27.11 | $17.03 |
| Revenue Next Year | $29.33 | $14.38 |
| P/E Ratio | ★ N/A | $86.85 |
| Revenue Growth | ★ 17.82 | 14.61 |
| 52 Week Low | $25.85 | $221.26 |
| 52 Week High | $57.20 | $362.41 |
| Indicator | KLAR | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 33.06 | 73.09 |
| Support Level | $26.83 | $358.36 |
| Resistance Level | $28.97 | $361.55 |
| Average True Range (ATR) | 1.67 | 8.11 |
| MACD | -0.30 | 2.17 |
| Stochastic Oscillator | 1.45 | 96.63 |
Klarna is the largest pure-play in the buy now, pay later space. The company operates a two-sided network with a payment method at its core, but it is ultimately a lender. Merchants sign up with Klarna to increase turnover in their stores. Primarily, Klarna can provide merchants with higher conversion rates and average order values relative to other payment methods. Some merchants enter a symbiotic relationship with Klarna, advertising its brand on the product page to drive conversion and to benefit from Klarna's brand value in the merchant's sales funnel. Customers use Klarna for its ease of use, quick access to credit, zero-interest financing, and lower reminder fees.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.